UNSPSC 51401516: Clonazepam

This classification denotes a benzodiazepine and anticonvulsant agent with the molecular formula C15H10ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PE9FDE8GB, chemically known as 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2h-1,4.benzodiazepin-2-one but generally known as clonazepam, which bears US NIH Compound Identifier 2802. European Medicines Agency schedules Clonazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06728MIG.

UNSPSC 51401516 Clonazepam (Commodity) represents pharmaceutical products that state and local governments procure for public health, community health, and pharmacy benefit programs. Recent activity under this code involves direct procurement of pharmaceutical inventory and participation in cooperative purchasing agreements that establish master vendor relationships for multi-state distribution. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. The scope of work encompasses supply of brand and generic pharmaceutical products meeting FDA manufacturing standards, compliance with Drug Supply Chain Security Act requirements, and fulfillment through authorized pharmaceutical wholesalers with quarterly or ongoing delivery schedules to public health facilities.

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for delivery to the Seminole County Community Health Building, with a two-year term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations, indicating state interest in alternative supply-chain models for pharmaceutical procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and pricing weighted 75 percent on competitiveness.